SPINT1 Antibodies

Kunitz-type protease inhibitor 1 (SPINT1)

Inhibitor of HGF activator.

Also acts as an inhibitor of matriptase (ST14).

.

Gene Information

Human
Gene Name:	SPINT1
Uniprot:	O43278
Entrez:	6692

Family

Belongs to:
No superfamily

Alternative Names

HAI; HAI1; HAI-1; hepatocyte growth factor activator inhibitor 1; Hepatocyte growth factor activator inhibitor type 1; kunitz-type protease inhibitor 1; MANSC2; serine peptidase inhibitor, Kunitz type 1; serine protease inhibitor, Kunitz type 1; SPINT1

Molecular Weight

Mass (kDA):
58.398 kDA

Genomic Context

Human
Location:	15q15.1
Sequence:	15; NC_000015.10 (40844043..40858207)

Subcellular Localizations

Secreted.

Diseases

• Malignant Neoplasms
• Neoplasms
• Carcinoma
• Cell Invasion
• Prostatic Neoplasms
• Malignant Neoplasm Of Prostate
• Neoplasm Metastasis
• Neoplasm Invasiveness
• Malignant Neoplasm Of Breast
• Adenocarcinoma
• Tumor Progression
• Mammary Neoplasms

• Malignant Paraganglionic Neoplasm
• Colorectal Cancer
• Colorectal Neoplasms
• Cell Transformation, Neoplastic
• Ovarian Neoplasm
• Carcinogenesis
• Hyperplasia

Pathways

• Localization
• Regeneration
• Proteolysis
• Cell Proliferation
• Zymogen Activation
• Invasive Growth
• Coagulation
• Angiogenesis
• Epithelial To Mesenchymal Transition
• Tissue Regeneration
• Cell Growth
• Keratinization
• Neural Tube Closure

• Translation
• Cell Motility
• Wound Healing
• Blood Coagulation
• Tissue Morphogenesis
• Tube Closure
• Secretion

PTMs

• Cleavage
• Phosphorylation

• Biotinylation
• Glycosylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SPINT1

Best Uses of the SPINT1 Marker

If you're new to immunohistochemistry, you may be wondering, "What's the SPINT1 marker?" It is a simple protein to detect, which is the good news. It's used in clinical and research applications. Researchers continue to experiment with the protein to find out how it functions. Learn more about it here! Here are the top uses of SPINT1 as well as how you can use them.

SPINT1 Marker

While most cancers have decreasing rates of incidence, cutaneous malignancy is one of those rarest forms of cancer. Many types of cancer can be linked to the serine protease inhibitor, Kunitz-type 1, 1 (SPINT1), that inhibits the activity SGA. Zebrafish are a unique model to show the effects Spint1a insufficient, including early transformation, progression, invasion, and metastatic disease.

Researchers have demonstrated that mutations in SPINT1 cause altered tumor immune microenvironment which can lead to poor patient survival. They found that a deficiency of SPINT1 promotes tumor cell transformation and regulates crosstalk between the immune system and tumor cells. SPINT1 regulates both cell autonomous as well as nonautonomous functions, which is a novel therapeutic target in SKCM.

The SPINT1 marker was first detected in plasma samples taken from a high risk cohort in the United Kingdom. The participants had been previously diagnosed with hypertension or fetal ischemia. Participants gave written consent to participate. High maternal blood pressure and other clinical characteristics indicated that they were highly susceptible to infection. This study was conducted on women with high-risk pregnancies. SPINT1 is an excellent diagnostic test.

Clinical Applications

SPINT1 can be used to inhibit serine-peptidase. It is commonly used to screen patients for colorectal disease. Its expression is associated to cancer risk. This marker is also known as Kunitz type 1 antisenseRNA. This marker was generated using real time quantitative polymerase chain reactions (RT-qPCR). A group of patients with colorectal tumors was tested in the SPINT1–AS1 research. The median SPINT1 level was 57.764pg/mL among patients who tested positive. The IQR range for SPINT1 was 42,212 to 91,356 pg/mL. The median SPINT1 value in infants with AGA, however, was 107 062 pg/mL.

Studies of preeclampsia and FGR have shown that circulating SPINT1 is decreased in women with concomitant disease. FGR is a major reason for stillbirths. Preeclampsia occurs in women who are born before 34 weeks gestation. In addition, women with preeclampsia and FGR who develop growth restriction have lower levels of SPINT1 than women without FGR.

SGA can also lead to placental failure, which is associated with preeclampsia and poor fetal health. SPINT1, a highly-expressed placental protein is involved in placental dysfunction. SPINT1 inhibition is associated in murine models with reduced placental growth. However, in preeclampsia it is unclear if there is a link between SPINT1 levels, placental insufficiency, and SPINT1 levels.

MACC1 expression was negatively correlated in GC tissues with SPINT1. MACC1 expression declined with TNM stage, while SPINT1 was expressed at a higher level. SPINT1 was also negatively associated with MACC1, a gene related to cell migration and attachment. These results suggest that SPINT1-based markers for GC could have a significant impact upon cancer risk assessment.

In addition to being associated with cancer risk, SPINT1-AS1 expression has also been linked to cancer progression and prognosis. This protein may therefore be a potential candidate biomarker and molecular treatment target. The research continues. The SPINT1–AS1 gene is highly expressed in CRC tissues. SPINT1 - AS1 expression may be a useful diagnostic marker for CRC patients.

Gene Ontology

Annotation is the report of a relationship between a gene product and a biological type. The GO terminology reflects the process of establishing this connection through experimental analysis on actual instances of the gene products. It is possible to analyze knowledge more precisely by understanding the role of instances. Gene product ontologies are formed by combining evidence across different types and their roles as part of biological processes.

TRIzol was used for the isolation of RNA from GC cell membranes. The RNA was subjected qRT-PCR using a SYBR Green dye made by Takara, Japan. Primers for MACC1 as well as SPINT1 were developed to bind to the appropriate gene sequences. The SPINT1 marker has been detected using the MACC1 & SPINT1 primes. The primer sequences were TTAGACGAGCGCAU-3', TTAGAGAGGGTCAGGTCAGGTAGGAATGTTC.

In the tabs that correspond, you will find GO classifications and a summary list of genes with SPINT1 displayed. You can also use the KEGG pathway tab to view information about known signaling pathways. This tab includes the pathway name, KEGG pathway ID, as well as a link to KEGG's website. Once you have found the gene with known functional activity you can perform a new research and analyze its underlying function.

MACC1 gene expression and SPINT1 gene expression combined increased the prognostic values of the MACC1 marker and SPINT1 marker. Both genes showed improved prognostic value, and when combined, SPINT1 and MACC1 expression was significantly better than SPINT1 expression alone. This combination may have greater prognostic value in GC patients. This is a significant step in the field of research into tumor prognosis.

MACC1 and SpINT1 have been associated with HGF/cMet pathways in many cancers. It is not known if they can work together. This could make them potentially attractive targets for therapeutic intervention. Although there is a lot evidence supporting these markers as prognostic factors for ESCCs, their functional relationship is still unknown. SPINT1 may be expressed in ESCC cells, which could help with treatment of a variety different cancers.

Immunohistochemistry

ELISA involves making decisions at almost all stages. For a successful experiment, it is important to choose the best sample preparation method, blocking buffer and antibody concentration. Boster Bio optimization guide can help answer your questions and optimize your ELISA experiments. Start with the free ELISA primer.